Exclusive
Egyptian court orders closure of news site Mada Masr and fines editor Lina Attalah, sparking international outcry Egyptian court orders closure of news site Mada Masr and fines editor Lina Attalah, sparking international outcry Indonesia’s Nuclear Deal with Russia is Fraught with Concerns Indonesia’s Nuclear Deal with Russia is Fraught with Concerns Amazon mining boss wanted by Brazil for sheltering Jair Bolsonaro’s spy chief has businesses, properties in Florida Amazon mining boss wanted by Brazil for sheltering Jair Bolsonaro’s spy chief has businesses, properties in Florida
Current Affairs

GSK licenses Chinese firm’s cancer drug in US$750 million deal

British pharmaceutical giant GSK has agreed to acquire a cancer drug from Chinese firm Chimagen Biosciences in a deal worth up to US$750 million, underscoring…

By Samantha Johnson / September 16, 2026

British pharmaceutical giant GSK has agreed to acquire a cancer drug from Chinese firm Chimagen Biosciences in a deal worth up to US$750 million, underscoring China’s emergence as a global player in biotechnology.

GSK announced plans on Tuesday to buy full global rights to a “potential best-in-class” T-cell engager (TCE) from Chengdu-based Chimagen, targeting treatment for multiple myeloma, a type of blood cancer.

TCEs work by binding T cells, a kind of white blood cell, directly to cancer cells, triggering the immune system to attack the cancer. While current TCEs are effective at treating multiple myeloma, they often cause major side effects, and Chimagen’s new drug shows promise in both improved tolerability and more durable results, according to GSK.

GSK will pay an undisclosed upfront fee to develop and commercialise Chimagen’s new TCE assets, followed by payments based on the drug’s successful development and commercialisation, the company said. The programme is expected to enter phase one trials next year.

Don't Miss: